Compare Novo Nordisk A/S (NVO) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Upwork Inc — how do they compare? Novo Nordisk A/S trades at $38.49 (market cap $165.31B), while Upwork Inc trades at $8.65 (market cap $1.07B). The key difference: Novo Nordisk A/S is far larger — about 154.5× Upwork Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Upwork Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Upwork Inc for 38 Days on average.
| NVO | UPWK | |
|---|---|---|
Market Cap | $165.31B | $1.07B |
Volume | 11,432,838 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $63.98 | $22.11 |
52-Week Low | $35.29 | $7.84 |
Typical Hold Time | 116 Days | 38 Days |
Enterprise Value | $179.56B | $833.01M |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Upwork (UPWK) trades at $8.62, up 2.62% today, with a bearish technical signal despite recent earnings beat. The company maintains strong profitability with 77.21% gross margins and 12.93% net income margin, though revenue growth has stalled at $787M for 2026. Recent insider selling and securities fraud investigations create headwinds, while analyst consensus remains positive with a $9.64 price target.
The stock presents a mixed outlook with attractive valuation metrics (P/E 10.99, P/S 1.48) offset by AI-driven competitive threats and declining active clients. Near-term resistance at $9 and support at $8 will be critical, with institutional accumulation by Bank of America providing some stability amid management selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
